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ABSTRACT
Introduction COVID-19 can cause severe acute 
respiratory failure requiring management in intensive 
care unit with invasive ventilation and a 40% mortality 
rate. Cardiovascular manifestations are common and 
studies have shown an increase in right ventricular (RV) 
dysfunction associated with mortality. These studies, 
however, comprise heterogeneous patient groups 
with few requiring invasive ventilation. This study will 
investigate the prevalence and prognostic significance of 
RV dysfunction in ventilated patients with COVID-19 which 
may lead to targeted interventions to improve patient 
outcomes.
Methods and analysis This prospective multicentre 
observational cohort study will perform transthoracic 
echocardiography (TTE) in 150 patients with COVID-19 
requiring invasive ventilation for more than 48 hours. 
RV dysfunction will be defined as TTE evidence of RV 
dilatation along with the presence of septal flattening. 
Baseline demographics, disease severity data and clinical 
information relating to proposed aetiological mechanisms 
of RV dysfunction (acute respiratory distress syndrome 
(ARDS), disordered coagulation, direct myocardial injury 
and ventilation) will be collected and analysed.
Primary outcome measures include the prevalence of RV 
dysfunction and its association with 30- day mortality. 
Exploratory outcome measures will investigate the 
association of the proposed aetiological mechanisms of RV 
dysfunction to the primary outcomes.
Prevalence of RV dysfunction will be determined along 
with 95% Clopper- Pearson CIs and 30- day survival will 
be analysed using logistic regression adjusting for patient 
demographics, phase of disease and baseline severity of 
illness. The role of potential aetiological factors (ARDS, 
disordered coagulation, direct myocardial injury and 
ventilation) in relation to the primary outcomes will be 
analysed using logistic regression.
Ethics and dissemination Approval was gained from 
Scotland A Research Ethics Committee (REC reference 
20/SS/0059). Findings will be disseminated by various 
methods including webinars, international presentations 
and publication in peer- reviewed journals.
INTRODUCTION
In December 2019, the first case of a novel 
COVID-19 caused by the SARS- CoV-2 virus 
was identified in Wuhan, China.1 Although 
the majority of cases are mild, approximately 
5% of confirmed cases will require intensive 
care unit (ICU) admission, with severe acute 
respiratory failure (SARF) being the promi-
nent feature.2 As of 27 September 2020 there 
were over 32.7 million cases worldwide with 
over 990 000 confirmed deaths.3 On 19 June 
2020, over 11 500 patients had been treated in 
UK critical care units.4 5 Unfortunately, in line 
with other countries, UK figures have demon-
strated extremely poor ICU outcomes with 
mortality rates of around 40%.4
Although not always classical in presenta-
tion, the acute respiratory distress syndrome 
(ARDS) is widely accepted to be the usual 
cause of SARF in patients with COVID-19.6 
Along with respiratory symptoms, cardiovas-
cular manifestations are also common and 
may adversely impact prognosis.7–9 In ARDS, 
the more susceptible right ventricle (RV) 
Strengths and limitations of this study
 ► Includes the most severely ill patients with 
COVID-19 disease; a patient group which are under- 
represented in other studies of right ventricular (RV) 
function in patients with COVID-19.
 ► Pragmatic study and primary outcome, re-
flecting clinical practice of intensive care unit 
echocardiography.
 ► Appropriately statistically powered.
 ► RV function is dynamic.
 ► As with all COVID-19 research, recruitment of ade-
quate participant numbers may be hampered due to 
the ‘passing of the peak’ of the COVID-19 pandemic 
in the UK but new cases continue to emerge.
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is subject to impaired function due to increased after-
load.10 11 RV dysfunction is known to be an independent 
predictor of mortality in the non- COVID-19 setting and 
increasing ARDS severity is associated with increased 
frequency of RV dysfunction.12–15
Recent studies have shown that RV dysfunction is 
a common finding in patients with COVID-19 and it 
increases mortality.9 16 17 While no single causative factor 
has been elucidated, there are several potential aeti-
ological factors which have been shown to increase RV 
afterload and impair RV contractility, with both factors 
leading to RV dysfunction. ARDS,10 18 19 pulmonary 
microthrombosis and macrothrombosis,20–24 and positive 
pressure ventilation with positive end- expiratory pres-
sure18 25 have all been shown to increase RV afterload 
with RV contractility being depressed by direct myocar-
dial injury.7 26 27 Previous studies addressing RV dysfunc-
tion in patients with COVID-19 included heterogeneous 
groups of patients of varying disease severity, of whom 
only a small proportion required mechanical ventilation. 
No adequately powered study has prospectively explored 
the incidence of RV dysfunction and its association with 
mortality in ventilated patients with COVID-19. Further 
investigation and exploration of causative mechanisms 
may allow targeted interventions to improve outcomes 
for this patient group.12 19 28 29
Hypothesis
Right ventricular failure is common in patients ventilated 
with COVID-19 and is associated with increased mortality. 
In examining this hypothesis, we will explore potential 
mechanisms for RV dysfunction in this patient group.
METHODS AND ANALYSIS
Summary: A multicentre prospective observational study 
in ventilated patients with COVID-19 in participating 
Scottish ICUs.
Centre(s): 15 participating ICUs in Scotland.
Study status: This is a planned study that was granted 
ethical approval on 5 June 2020 and grant funding on 27 
May 2020. Recruitment commenced in September 2020.
Selection of study subjects
Inclusion criteria
Patients >16 years with confirmed SARS- CoV-2 infection 
with SARF requiring tracheal intubation and positive 
pressure ventilation in intensive care for more than 48 
hours, but not more than 14 days will be eligible for inclu-
sion in the study.
Exclusion criteria
Patients for whom informed consent is unable to be 
provided either directly or on their behalf by a rela-
tive/welfare guardian will be excluded. Other exclusion 
criteria include:
 ► Pregnancy.
 ► Ongoing participation in any investigational research 
that may undermine the scientific basis of the study.
 ► Prior participation in the COVID- RV study.
 ► Requirement for extracorporeal membrane oxygena-
tion support for respiratory or cardiovascular failure.
 ► Patient at end of life and not expected to survive 
longer than 24 hours.
Study conduct
Recruitment
Potential participants will be identified and recruited by 
the local treating clinical team during their admission to 
intensive care.
Consent
Prospective informed consent will be obtained. As target 
patients will be critically ill in the ICU, it is unlikely that 
they themselves will be able to provide informed consent. 
Consent will be sought from the patient’s legally desig-
nated representative, most likely a relative, either in 
person or via telephone. Further consent will then be 
sought from the study participants if they recover suffi-
ciently and regain capacity to provide consent.
Medical management
Medical management will be according to the standard 




Participants recruited to take part in the study will 
undergo a single transthoracic echocardiogram (TTE) 
to determine the presence or absence of RV dysfunc-
tion. This will be undertaken after 48 hours but before 
14 days of intubation and invasive ventilation. TTE will 
be performed by a range of appropriately competent 
practitioners including (but not exclusively) intensive 
care clinicians, cardiologists and specialist echocardiog-
raphers reflecting the clinical practice of bedside echo-
cardiography in intensive care. For the purposes of the 
primary outcome, imaging required will be in keeping 
with the protocol required for a focused intensive care 
echo scan.30 A secondary quantitative data set will be 
collected where echocardiography skills allow.
Laboratory sampling
High sensitivity troponin (I or T) and, where available, natri-
uretic peptides (brain natriuretic peptide (BNP) or N- ter-
minal pro b- type natriuretic peptide (NT- proBNP)) will be 
measured as part of routine blood sampling on the same day 
as TTE.
Data collection and management
Data collection will be performed by the local study 
team on case report forms (CRFs) which will be filed 
and securely stored at participating sites. The data will 
be anonymised at site and a unique alphanumeric study 
number allocated. Completed CRFs will then be entered 
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onto a secure online database in a linked anonymised 
form. Electronic data will be stored in an encrypted and 
anonymised format for 10 years following the completion 
of the trial. At the end of this period, the data set will be 
destroyed and this will be performed to DoD 5220.22- M 
standards. The study will adhere to all data protection 
regulations and all data will be held in accordance with 
the General Data Protection Regulation (2018).
Clinical data
Clinical data involve baseline demographic data and 
chronic comorbidities, ICU admission information, 
severity of illness and acute comorbidities and follow- up 
data. Clinical data relating to the proposed mechanisms 
of RV dysfunction will also be collected, specifically 
regarding ARDS, disordered coagulation, myocardial 
injury and ventilation (table 1).
Laboratory data
Laboratory data will be obtained from the local biochem-
istry and haematology laboratory reporting systems on 
the day of echocardiography and at follow- up.
ECG data
A 12- lead ECG will be anonymised and transferred 
electronically to the research team for further analysis. 
Abnormalities in rate, rhythm, conduction and repolar-
isation (ST- segment deviation, T- wave inversion) will be 
classified, blind to other clinical data.
Echocardiography data
A focused echocardiography data set will be used to 
answer the primary outcome (table 2). If available, and 
the echocardiographer’s competency and experience 
permit, further quantitative measures of RV function will 
be obtained at this time (table 3).
As part of the data set, a parasternal short axis and 
apical four- chamber (A4C) ‘loop’ will be recorded and 
saved. For the A4C loop this will take the form of an 
RV- focused view. For both, the images will be optimised, 
have ECG monitoring present throughout and the frame 
rate should be maximised; both will be recorded for four 
beats.31 These data will be anonymised and transferred 
electronically to the research team for further analysis.
Study outcomes
Primary outcome
The primary outcome of the study is the prevalence of RV 
dysfunction in ventilated patients with COVID-19 and its asso-
ciation with 30- day mortality. RV dysfunction will be defined 
as TTE evidence of RV dilatation along with the presence of 
septal flattening (in systole, diastole or both). RV dilatation 
will be determined from the A4C view at end diastole and will 
be defined as when the RV:LV ratio is >1:1.
Justification for primary outcome
TTE is the mainstay of RV imaging in ICU; it is non- invasive, 
free from ionising radiation, widely available and low cost. 
The ability to bring the echo machine to the patient bedside 
means it is the preferred method for diagnosis of RV dysfunc-
tion in ICU patients.32 TTE can determine RV dilatation 
and can detect eccentric movement of the interventricular 
septum. The combination of RV dilatation and eccentric 
septal motion is often referred to as acute cor pulmonale and 
is a widely reported measure of RV dysfunction in patients 
with respiratory failure in intensive care.13 14 33–37
Exploratory outcomes
Exploratory outcome measures largely relate to the 
association of the proposed aetiological factors, namely 
Table 1 Clinical and laboratory data to explore 
mechanisms of RV dysfunction
Mechanistic 
category Clinical and laboratory data
ARDS Requirement for prone ventilation
Murray lung injury score and components
Requirement for paralysis
Compliance
Arterial blood gas analysis







Confirmed or suspected pulmonary 
thromboembolism
Prothrombin time (PT)/activated partial 
thromboplastin time (aPTT)
Platelet count
Myocardial injury LV function (from TTE)
  ScvO2
Natriuretic peptides (BNP or NT- proBNP)
Troponin




Ventilation Fraction of inspired oxygen (FiO2)
Ventilatory mode
Positive end- expiratory pressure
  Peak airway pressure
  Driving pressure
  Respiratory rate
Clinical and laboratory data to explore mechanisms of 
RV dysfunction in each mechanistic category: ARDS, 
disordered coagulation, myocardial injury and ventilation.
ARDS, acute respiratory distress syndrome; BNP, brain 
natriuretic peptide; LV, left ventricle; NT- proBNP, N- terminal 
pro b- type natriuretic peptide; RV, right ventricle; TTE, 
transthoracic echocardiogram.
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ARDS, disordered coagulation, direct myocardial injury 
and ventilation, to RV dysfunction and 30- day mortality. 
The association of cardiac biomarkers (troponin T or I 
and natriuretic peptides (BNP or NT- proBNP)) to the 
primary outcome measures will also be evaluated.
Saved echo loops will be analysed centrally at the host 
institution, blinded and anonymised under the super-
vision of British Society of Echocardiography (BSE)- 
accredited echocardiographers. In addition to exploring 
the utility of other echocardiographic parameters such as 
eccentricity index and the tricuspid annular plane systolic 
excursion/pulmonary artery systolic pressure ratio, 2D 
speckle tracking will be performed for analysis for RV free 
wall and global longitudinal strain. Image analysis will 
be performed on the TomTec 2D Cardiac Performance 
Analysis platform. Agreement on classification of echo-
cardiographic parameters between critical care echocar-
diographers at each study site and echocardiographers at 
the host centre will be explored.
Statistical considerations
All statistical analyses will be performed in conjunction 
with the Robertson Centre for Biostatistics at the Univer-
sity of Glasgow.























Basic echocardiography data set to allow determination of 
the primary outcome measures.
LV, left ventricle; RV, right ventricle.




  RV end diastolic area cm2
  RV end systolic area cm2
  Fractional area change (FAC) %
  Unable to assess
Free text: Image quality, RWMA, McConnell’s sign, presence 
of clot, and so on









  RVD1 mm
  RVD2 mm
  RVD3 mm
  Unable to assess









Free text: Method of assessing TR (vena contracta, 
quantitative (EROA, ERV), hepatic vein flow)
Right ventricular index of myocardial 
performance (RIMP)/Tei index
  PWD
  Tissue Doppler
  Unable to assess
IVC diameter
  IVC diameter cm




  Unable to assess
RVOT acceleration time ms
Unable to assess
LV function and size
  2D
   LVIDd cm
   LVIDs cm
   LVFS %
  Unable to assess
  Biplane
   LVEDV mL
Continued
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Sample size calculation
Sample size selection is required to be a pragmatic 
balance of maximising available information versus the 
prompt delivery of the study and reporting of results 
to the clinical workforce. Given the number of patients 
admitted to ICU in Scotland during the early stages of the 
pandemic, it is realistic to recruit 120–150 patients across 
participating sites.5
Prevalence of RV dysfunction: With a sample size of 
120, if the proportion of patients with RV dysfunction 
was 50%, the 95% CI around the estimated rate would 
be 40.7% to 59.3%, if the proportion was 25% the 95% 
CI would be 17.5% to 33.7%. With a sample size of 150 
patients, the 95% CIs would be (41.7 to 58.3) and (18.6 
to 33.1), respectively.
Association with mortality: Table 4 demonstrates the 
differences in mortality rates that could be detected in a 
sample size of 120–150 patients at a significance level of 
5% and proportions of patients with RV dysfunction of 
25% and 50%, assuming an overall mortality rate of 50% 
(as presented in the recent UK Intensive Care National 




The proportion of ventilated patients with COVID-19 
who have RV dysfunction will be determined, with a 95% 
CI (Clopper- Pearson method). The association of RV 
dysfunction with 30- day mortality will then be analysed 
using logistic regression analysis predicting 30- day ICU 
mortality from presence or absence of RV dysfunction, 
adjusting for patient demographics, phase of disease and 
baseline severity of illness.
Exploratory outcomes
To assess the role of potential aetiological factors (ARDS, 
disordered coagulation, direct myocardial injury and 
ventilation) for RV dysfunction, the relation of each 
measure of the aetiological factors to the outcomes will 
be analysed in the same way as for the primary outcome. 
A more in- depth analysis will include carrying out a prin-
cipal component analysis for all measures within each 
factor, in order to create one single measure (the first 
principal component) representing each factor. The rela-
tion of these to the outcomes will be assessed in regres-
sion analyses analogously to the ones described above. 
This will be done for each factor separately and also in 
combination. Other approaches, for example, the least 
absolute shrinkage and selection operator, for deter-
mining the role of the individual measures of all factors 
may be explored.39
The association of cardiac biomarkers with RV dysfunc-
tion will be analysed using logistic regression analysis 
predicting presence or absence of RV dysfunction from 
the biomarker level, adjusting for patient demographics, 
phase of disease and baseline severity. Association of the 
Echocardiography parameter Result
   LVESV mL
   LVEF %
  Unable to assess
Free text: Comments such as regional wall motion 
abnormality, valve pathology, and so on
Detailed echocardiography measures of RV function to 
be undertaken dependent on the echocardiographer’s 
competency and experience and if image quality allows.
EROA, estimated regurgitant orifice area; ERV, effective 
regurgitant volume; IVC, inferior vena cava; LV, left ventricle; 
LVEDV, left ventricular end- diastolic volume; LVEF, left 
ventricular ejection fraction; LVESV, left ventricular end- 
systolic volume; LVFS, left ventricular fractional shortening; 
LVIDd, left ventricular internal diameter diastolic; LVIDs, 
left ventricular internal diameter systolic; PA, pulmonary 
artery; PWD, pulse wave doppler; RV, right ventricle; RVOT, 
right ventricular outflow tract; RWMA, regional wall motion 
abnormality; TR, tricuspid regurgitation.
Table 3 Continued
Table 4 Indicative power
Sample size Power (%)
Number without RV 
dysfunction
Number with RV 
dysfunction
Mortality in 
patients without RV 
dysfunction
Mortality in patients 
with RV dysfunction OR
120 80 60 60 0.373 0.627 2.83
120 90 60 60 0.354 0.646 3.33
150 80 75 75 0.386 0.614 2.53
150 90 75 75 0.369 0.631 2.92
120 80 90 30 0.427 0.719 3.43
120 90 90 30 0.417 0.749 4.17
150 80 112 38 0.435 0.695 2.96
150 90 112 38 0.426 0.722 3.50
Differences in mortality rates that could be detected at a 5% significance level for sample sizes of 120 and 150, and proportions of patients with RV 
dysfunction of 25% and 50%, assuming an overall mortality rate of 50%.
RV, right ventricle.
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biomarkers with 30- day mortality will be analysed in a 
similar manner. To assess whether any association differs 
in the presence or absence of RV dysfunction, RV dysfunc-
tion and its interaction with the biomarker will be added 
to the model.
Patient and public involvement
Due to the nature of the current COVID-19 pandemic 
and the subsequent urgency to establish this study there 
was no patient or public involvement. Patients were not 
invited to comment on the study design and were not 
consulted to develop patient- relevant outcomes or inter-
pret the results. Patients were not invited to contribute to 
the writing or editing of this document for readability or 
accuracy.
ETHICS AND DISSEMINATION
Ethical approval was granted by the Scotland A Research 
Ethics Committee (REC reference 20/SS/0059) on 5 
June 2020.
The safety profile of all research interventions (TTE, 
collection of clinical information and blood specimens) 
is well established and therefore adverse event reporting 
is not applicable.
Given the nature of the current global pandemic we will 
endeavour to publish the prevalence of RV dysfunction 
in COVID-19 as soon as possible on completion of the 
study. Once the 30- day follow- up period is complete, the 
primary outcome will be published along with all avail-
able exploratory analyses. We envisage sharing findings 
with the critical care community at an early stage through 
a series of webinars.
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